1-(4-nitrophenyl)-3-pyridin-3-yl-propan-1-one | 238097-15-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-nitrophenyl)-3-pyridin-3-yl-propan-1-one
• 英文别名: 1-(4-Nitrophenyl)-3-(3-pyridinyl)-1-propanone；1-(4-nitrophenyl)-3-pyridin-3-ylpropan-1-one
• CAS: 238097-15-9
• 化学式: C₁₄H₁₂N₂O₃
• 分子量: 256.261
• InChiKey: ACPGESAWEZWCKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  75.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-nitrophenyl)-3-pyridin-3-yl-propan-1-one 在 ammonium acetate 、 sulfur 、 溶剂黄146 、 二乙胺 作用下， 以 乙醇 、 苯 为溶剂， 反应 19.5h， 生成 2-Amino-4-(4-nitro-phenyl)-5-pyridin-3-ylmethyl-thiophene-3-carbonitrile
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h
• 作为产物：
  描述：

  1-(4-硝基苯基)-3-吡啶-3-基丙烯酮 在 四(三苯基膦)钯 、 三正丁基氢锡 作用下， 以 四氢呋喃 为溶剂， 以50%的产率得到1-(4-nitrophenyl)-3-pyridin-3-yl-propan-1-one
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h

文献信息

• Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
  申请人：——

  公开号：US20040014756A1

  公开（公告）日：2004-01-22

  Compounds having the formula 1 are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• [EN] THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DES THIOPYRIMIDINE ET ISOTHIAZOLOPYRIMIDINE KINASES
  申请人：ABBOTT LAB

  公开号：WO2003080625A1

  公开（公告）日：2003-10-02

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶非常有用。本发明还公开了制备该化合物的方法，含有该化合物的组合物以及使用该化合物进行治疗的方法。
• Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors
  申请人：Michaelides R. Michael

  公开号：US20060276490A1

  公开（公告）日：2006-12-07

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还揭示了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS
  申请人：Abbott Laboratories

  公开号：EP1487841A1

  公开（公告）日：2004-12-22
• US7560552B2
  申请人：——

  公开号：US7560552B2

  公开（公告）日：2009-07-14